nasopharyngeal carcinoma |
20 |
cancer susceptibility genes |
13 |
early-age onset |
13 |
mst1r |
13 |
whole-exome sequencing |
13 |
chinese |
12 |
children |
11 |
epstein-barr virus |
11 |
adolescent |
10 |
allergy |
10 |
asparaginase |
10 |
human leukocyte antigens |
10 |
hypersensitivity |
10 |
pediatric |
9 |
hepatoblastoma |
8 |
lytic cycle |
8 |
medical sciences |
8 |
oncology medical sciences |
8 |
pediatrics |
8 |
epstein–barr virus |
7 |
humans |
7 |
relapse |
7 |
retrospective studies |
7 |
treatment outcome |
7 |
polymerase chain reaction |
6 |
adult |
5 |
antigens, cd56 - metabolism |
5 |
apoptosis |
5 |
candida |
5 |
chinese children |
5 |
ebv‐encoded small rna |
5 |
genome‐wide analysis |
5 |
hematopoietic stem cell transplantation |
5 |
hepatitis b virus |
5 |
hepatocellular carcinoma |
5 |
immunophenotyping |
5 |
leukemia |
5 |
lytic reactivation |
5 |
nucleic acid amplification |
5 |
pretreatment extent of disease |
5 |
renal abscess |
5 |
risk stratification |
5 |
sequencing |
5 |
surveillance |
5 |
vaccination |
5 |
aged |
4 |
anti-bacterial agents - therapeutic use |
4 |
antigens, neoplasm - metabolism |
4 |
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
autoimmune diseases |
4 |
autoimmune diseases - epidemiology - ethnology |
4 |
autophagy |
4 |
bacterial infections - epidemiology - ethnology |
4 |
bone marrow transplantation |
4 |
carcinoma, hepatocellular - epidemiology - pathology |
4 |
cd56 |
4 |
child |
4 |
child, preschool |
4 |
chronic |
4 |
combined modality therapy |
4 |
cord blood |
4 |
cyclosporin |
4 |
disease progression |
4 |
donor lymphocyte infusion |
4 |
ebv |
4 |
epithelial cancer |
4 |
epstein-barr virus (ebv) |
4 |
female |
4 |
graft versus tumor effect |
4 |
haploidentical |
4 |
haploidentical hematopoietic stem cell transplantation |
4 |
hepatic artery ligation |
4 |
hepatoblastoma - epidemiology - pathology |
4 |
histone deacetylase inhibitor |
4 |
hong kong - epidemiology |
4 |
hospitalization - statistics & numerical data |
4 |
immune thrombocytopenia |
4 |
immunoglobulins |
4 |
immunotherapy |
4 |
killer cells, natural - pathology |
4 |
klebsiella infections - complications - drug therapy - epidemiology |
4 |
klebsiella pneumoniae - drug effects |
4 |
leukoencephalopathy |
4 |
liver neoplasms - epidemiology - pathology |
4 |
liver tumors |
4 |
lymphoma, non-hodgkin - diagnosis - drug therapy - radiotherapy |
4 |
lymphoma, t-cell, peripheral - diagnosis - drug therapy - radiotherapy |
4 |
lytic induction therapy |
4 |
male |
4 |
methotrexate |
4 |
middle aged |
4 |
nasopharyngeal carcinoma (npc) |
4 |
natural killer cell lymphoma/leukaemia |
4 |
neuroblastoma |
4 |
neurological complications |
4 |
neutropenia |
4 |
neutropenia - epidemiology - ethnology |
4 |
nose neoplasms - diagnosis - drug therapy - radiotherapy |
4 |
posterior reversible encephalopathy syndrome |
4 |
prognosis |
4 |
rhabdomyosarcoma |
4 |
rhabdomyosarcoma - mortality - pathology - therapy |
4 |
romidepsin |
4 |
soft tissue neoplasms - mortality - pathology - therapy |
4 |
thalassemia - complications |
4 |
total body irradiation |
4 |
transarterial embolization |
4 |
transplant-related morbidity |
4 |
tumor markers, biological - metabolism |
4 |
tumor rupture |
4 |
11c-acetate |
3 |
acinic cell carcinoma |
3 |
aplastic anaemia |
3 |
atp-binding cassette transporters - analysis |
3 |
autologous |
3 |
beta 2-microglobulin - analysis |
3 |
beta-thalassemia |
3 |
cancer treatment |
3 |
case report |
3 |
cerebral thrombosis |
3 |
chemotherapy |
3 |
childhood acute lymphoblastic leukaemia |
3 |
childhood cancer |
3 |
chimerism |
3 |
congenital fibrosarcoma |
3 |
diabetes insipidus |
3 |
dysarthria |
3 |
embryonal sarcoma |
3 |
epidemiology |
3 |
epstein-barr virus infections - immunology |
3 |
fanconi anaemia |
3 |
formalin |
3 |
fungal infection |
3 |
gastric carcinoma |
3 |
genetic variation |
3 |
haematopoietic stem cell transplant |
3 |
hearing loss |
3 |
hemorrhagic cystitis |
3 |
hepatitis |
3 |
herpesvirus |
3 |
herpesvirus 4, human - classification - genetics - isolation & purification |
3 |
histocompatibility antigens class i - analysis |
3 |
hla class 1,immune escape |
3 |
immunodeficiency |
3 |
immunohistochemistry |
3 |
infectious mononucleosis |
3 |
interleukin 12 |
3 |
interleukin-10 |
3 |
interleukin-10 - analysis |
3 |
intestinal |
3 |
intrathecal |
3 |
iron chelation |
3 |
iron chelator |
3 |
jmml |
3 |
juvenile pernicious anaemia |
3 |
l-asparaginase |
3 |
liver tumour |
3 |
long-term complications |
3 |
lymphocyte transfusion |
3 |
lymphoma, t-cell - immunology |
3 |
magnetic resonance imaging |
3 |
mesenchymal hamartoma |
3 |
metastasis |
3 |
monosomy 7 |
3 |
myeloperoxidase deficiency |
3 |
nasal nk/t-cell lymphoma |
3 |
nasopharyngeal neoplasms - virology |
3 |
natural killer cells |
3 |
neurofibromatosis |
3 |
nose neoplasms - immunology |
3 |
positron emission tomography |
3 |
prematurity |
3 |
quality of life |
3 |
questionnaires |
3 |
rare tumor |
3 |
recurrence |
3 |
rhizopus |
3 |
salivary gland |
3 |
second cancer |
3 |
selective iga deficiency |
3 |
suberoylanilide hydroxamic acid |
3 |
t cell dysfunction |
3 |
tap 1 |
3 |
thalassemia - therapy |
3 |
transplantation |
3 |
transplantation, homologous |
3 |
vitiligo |
3 |
von willebrand disease |
3 |
wiskott-aldrich syndrome |
3 |
zygomycosis |
3 |
β2-microglobulin |
3 |
abdominal distension |
2 |
acute megakaryoblastic leukaemia (amkl) |
2 |
allogeneic hematopoietic stem cell transplantation |
2 |
allopurinol - therapeutic use |
2 |
angiogenesis |
2 |
antigens, cd - analysis |
2 |
antigens, cd2 - analysis |
2 |
antigens, cd3 - analysis |
2 |
antigens, cd56 |
2 |
antigens, differentiation, t-lymphocyte - analysis |
2 |
antigens, viral - genetics |
2 |
antimetabolites - therapeutic use |
2 |
asymptomatic primary infection |
2 |
autologous hematopoietic stem cell transplantation |
2 |
b cell lymphoma |
2 |
b lymphocyte |
2 |
beta-thalassemia - complications - drug therapy |
2 |
beta-thalassemia - diagnosis - drug therapy |
2 |
blf4 gene |
2 |
bllf1 gene |
2 |
bllf2 gene |
2 |
bolf1 gene |
2 |
brain tumor |
2 |
burkitt lymphoma |
2 |
cancer chemotherapy |
2 |
cardiac magnetic resonance imaging t2* (mri t2*) |
2 |
cardiac t2* |
2 |
carrier state |
2 |
case series |
2 |
cd4-cd8 ratio |
2 |
cd8+ t lymphocyte |
2 |
cell cycle |
2 |
chelation protocol |
2 |
chelation therapy - methods |
2 |
chickenpox vaccine - therapeutic use |
2 |
combined therapy |
2 |
controlled clinical trials as topic |
2 |
cytokines |
2 |
cytotoxic cell antigen |
2 |
deferasirox |
2 |
deferiprone (l1) |
2 |
deferoxamine (dfo) |
2 |
deferoxamine(dfo) |
2 |
dendritic cell |
2 |
diagnosis |
2 |
diarrhea |
2 |
dna, neoplasm - genetics |
2 |
dna-binding proteins - biosynthesis - genetics |
2 |
down syndrome |
2 |
dural sinus thrombosis |
2 |
epithelium - virology |
2 |
epstein-barr virus nuclear antigen (ebna)-3c |
2 |
epstein-barr virus nuclear antigens - biosynthesis - genetics |
2 |
ferritins - blood |
2 |
gastrointestinal |
2 |
gene deletion |
2 |
gene expression |
2 |
gene rearrangement |
2 |
gene rearrangement, b-lymphocyte, heavy chain |
2 |
gene rearrangement, gamma-chain t-cell antigen receptor |
2 |
gene rearrangement, t-lymphocyte |
2 |
gene transcription |
2 |
genes, viral |
2 |
genes, viral - genetics |
2 |
genotype |
2 |
graft-versus-host disease |
2 |
growth factor receptor |
2 |
heart diseases - diagnosis - etiology - prevention and control |
2 |
hematologic neoplasms - complications |
2 |
herpesvirus 4, human |
2 |
herpesvirus 4, human - genetics |
2 |
herpesvirus 4, human - genetics - metabolism - physiology |
2 |
herpesvirus 4, human - isolation & purification |
2 |
hodgkin disease - pathology - virology |
2 |
immunodominance |
2 |
immunodominance hierarchies |
2 |
in situ hybridization |
2 |
infliximab |
2 |
influenza vaccines - therapeutic use |
2 |
interferon gamma |
2 |
interleukin 10 |
2 |
iron chelating agents - administration and dosage - therapeutic use |
2 |
iron chelating agents - therapeutic use |
2 |
iron overload |
2 |
iron overload - drug therapy |
2 |
juvenile myelomonocytic leukaemia |
2 |
killer cells, natural |
2 |
killer cells, natural - cytology - immunology - virology |
2 |
killer cells, natural - immunology |
2 |
killer cells, natural - immunology - pathology |
2 |
killer cells, natural - pathology - virology |
2 |
leukocytes, mononuclear - virology |
2 |
lymphoblastoid cells |
2 |
lymphoid tissue - virology |
2 |
lymphoma - classification - immunology |
2 |
lymphoma - genetics - immunology - pathology |
2 |
lymphoma - immunology - pathology - virology |
2 |
lymphoma, extranodal nk-t-cell - pathology - therapy |
2 |
lymphoma, t-cell - genetics |
2 |
lymphoma, t-cell - genetics - immunology - pathology |
2 |
lymphoma, t-cell - genetics - immunology - pathology - virology |
2 |
lymphoma, t-cell - pathology - virology |
2 |
lymphoma, t-cell, peripheral - immunology - pathology - virology |
2 |
lytic and latent proteins |
2 |
magnetic resonance imaging - methods |
2 |
membrane glycoproteins - analysis |
2 |
membrane proteins - analysis |
2 |
nasal lymphomas |
2 |
nasopharyngeal neoplasms - pathology - virology |
2 |
necrosis |
2 |
neoplasm proteins - analysis |
2 |
neoplasm staging |
2 |
nk-cell lymphoma |
2 |
nkg2a |
2 |
nose - virology |
2 |
nose neoplasms - classification - immunology |
2 |
nose neoplasms - genetics - immunology - pathology |
2 |
nose neoplasms - genetics - immunology - pathology - virology |
2 |
nose neoplasms - genetics - virology |
2 |
nose/pathology |
2 |
npc |
2 |
perforin |
2 |
phenotype |
2 |
poliovirus vaccines - therapeutic use |
2 |
poly(a)-binding proteins |
2 |
polycythaemia vera |
2 |
polyfunctional t cells |
2 |
polymorphism, genetic - genetics |
2 |
polymorphism, restriction fragment length |
2 |
pore forming cytotoxic proteins |
2 |
post-transplant lymphoproliferative disorder |
2 |
proteins |
2 |
receptors, antigen, t-cell - analysis |
2 |
receptors, antigen, t-cell - genetics |
2 |
renal tubular dysfunction |
2 |
ribosomal proteins |
2 |
rna, messenger - genetics - metabolism |
2 |
rna, viral - analysis |
2 |
rna-binding proteins - analysis |
2 |
serum electrolyte |
2 |
serum ferritin (sf) |
2 |
serum ferritin(sf) |
2 |
steroid dependent |
2 |
steroid refractory |
2 |
susceptibility |
2 |
t-cell lymphoma |
2 |
t-cell receptor |
2 |
t-lymphocyte subsets - immunology |
2 |
t-lymphocytes - pathology - virology |
2 |
t-lymphocytes, cytotoxic - immunology - pathology - virology |
2 |
targeted therapy |
2 |
thalassemia |
2 |
tia- 1 |
2 |
trans-activators - biosynthesis - genetics |
2 |
transcription, genetic |
2 |
transient myeloproliferative disease |
2 |
transplant complication |
2 |
trisomy 21 |
2 |
tuberculosis |
2 |
tumor lysis syndrome - mortality - prevention and control |
2 |
urate oxidase - adverse effects - therapeutic use |
2 |
viral gastroenteritis |
2 |
viral matrix proteins - biosynthesis - genetics |
2 |
viral matrix proteins - genetics |
2 |
viral proteins |
2 |
virus diseases - prevention and control |
2 |
virus latency |
2 |
β-thalassaemia |
2 |
acute lymphoblastic leukaemia |
1 |
acute lymphoblastic leukemia |
1 |
airway obstruction |
1 |
anterior mediastinal mass |
1 |
antineoplastic agents - pharmacology |
1 |
apoptosis - drug effects |
1 |
asian continental ancestry group |
1 |
b-lymphocytes - virology |
1 |
bortezomib |
1 |
cancer hallmarks |
1 |
carcinoma - drug therapy - virology |
1 |
central nervous system |
1 |
children and adolescents |
1 |
class i histone deacetylase inhibitor |
1 |
clinical trials on targeted therapies |
1 |
complete resection |
1 |
dual-responsive fluorescent ebv probe |
1 |
ebna1 |
1 |
ebna1-targeting agent |
1 |
ebna3 |
1 |
ebv latency |
1 |
ebv-specific lytic inducer |
1 |
efs |
1 |
endemic burkitt lymphoma |
1 |
endoplasmic reticulum stress |
1 |
epstein–barr virus (ebv) |
1 |
gene expression profiling |
1 |
genetic predisposition to disease |
1 |
hematology |
1 |
herpesvirus 4, human - drug effects |
1 |
herpesvirus 4, human - pathogenicity |
1 |
histone deacetylase 6 |
1 |
histone deacetylase inhibitors - chemistry |
1 |
histone deacetylase inhibitors - pharmacology |
1 |
histone deacetylases - metabolism |
1 |
hodgkin lymphoma |
1 |
host-pathogen interactions |
1 |
incidence |
1 |
interhospital transport |
1 |
interleukin-12 - genetics - metabolism |
1 |
intraspinal hemorrhage |
1 |
latency |
1 |
lumbar puncture |
1 |
lymphoblastoid cell lines |
1 |
lymphoproliferative disease |
1 |
lymphoproliferative diseases |
1 |
lytic cycle reactivation |
1 |
lytic proteins |
1 |
marginal zone lymphoma |
1 |
mediastinal mass |
1 |
mycobacterium tuberculosis |
1 |
nasopharyngeal neoplasms - metabolism |
1 |
non-hodgkin lymphoma |
1 |
oncovirus |
1 |
osteonecrosis |
1 |
outcome |
1 |
pediatric solid tumors |
1 |
polymorphism, genetic |
1 |
postdural puncture headache |
1 |
precursor cell lymphoblastic leukemia-lymphoma |
1 |
proteasome endopeptidase complex - chemistry |
1 |
proteasome inhibitor |
1 |
refractory and relapsed non-hodgkin lymphoma |
1 |
risk factors |
1 |
rna, viral - genetics - metabolism |
1 |
saha |
1 |
stem cell transplant |
1 |
stem cell transplantation |
1 |
subdural hematoma |
1 |
superior vena cava obstruction |
1 |
survival |
1 |
survivin |
1 |
t(1;19) |
1 |
t-/nk-/b-cell non-hodgkin lymphoma |
1 |
tcf3-pbx1 |
1 |
transplant |
1 |
treatment |
1 |
viral-targeted strategies |
1 |
watch-and-wait |
1 |
young adult |
1 |